Radiologists

New Nanostructured Lipid Carrier System Could Improve GIST Treatment

Researchers developed a new nanostructured lipid carrier system to deliver imatinib to patients with gastrointestinal stromal tumors (GISTs), as published in Nanomaterials. A small amount of imatinib loaded into the new system will be better than imatinib alone, they said. Imatinib is extensively used for the treatment of GIST. However, the drug can cause side…

Targeting MRP1 Has Therapeutic Potential in Imatinib-Resistant GIST

The N6-methyladenosine (m6A) modification of the multidrug resistance-associated protein 1 (MRP1) mRNA promotes drug resistance in gastrointestinal stromal tumors (GISTs), a new study published in Cancer Letters found. This suggests that MRP1 could be a potential therapeutic target for imatinib-resistant GIST. GISTs are abnormal mesenchymal cell growths of the gastrointestinal tract. Patients undergo complete surgical…

New Cholangiocarcinoma Noncoding RNA Could Become an Intervention Target

Proteasome 20S subunit alpha 3 antisense RNA 1 (PSMA3-AS1) represents a new cancer-promoting long noncoding RNA in cholangiocarcinoma, as published in Aging. This finding suggests that PSMA3-AS1 could be a target for the treatment of the disease. It is already known that long noncoding RNAs including PSMA3-AS1 play a crucial role in the development and…

Postoperative CA19-9 Shows Prognostic Significance in Cholangiocarcinoma

Researchers concluded that the levels of the carbohydrate antigen 19-9 (CA19-9) had a better prognostic performance in patients with intrahepatic cholangiocarcinoma when measured postoperatively, as published in Frontiers in Oncology. “Patients with elevated preoperative CA19-9 that normalizes after curative resection are associated with comparable long-term survival outcomes compared to those with normal preoperative CA19-9, whereas…

Conditional Survival Rates Vary Following Intrahepatic Cholangiocarcinoma Surgery

Conditional survival rates vary across stage categories in patients with nonmetastatic intrahepatic cholangiocarcinoma following surgery, according to a new study published in the Scandinavian Journal of Gastroenterology. This finding is important as it has implications in individualized clinical counseling and decision‐making for the disease. To examine the conditional survival rates of patients with nonmetastatic intrahepatic…

CEA Levels May Increase in MTC After Successful Selpercatinib Treatment

Patients with medullary thyroid cancer (MTC) who are treated with selpercatinib and have an objective tumor response can have a lasting increase in serum carcinoembryonic antigen (CEA) levels, according to a new case study published in European Thyroid Journal. “The mechanism behind this unexpected rise in CEA level remains unknown,” the researchers wrote. Normally, levels of…

Researchers Associate Large Benign MTC Tumor With Certain Mutation

A rare case of large a medullary thyroid cancer (MTC) tumor with extremely elevated calcitonin levels but no signs of metastization was recently reported in the journal Cureus. “This case report highlights the value of genetic studies on disease prognostication and the need for comprehensive research studies on genomic profiling in MTC to better understand…

Preoperative Computed Tomography May Underestimate Gastric GIST Size

Researchers suggested that computed tomography (CT) may not be a reliable tool to estimate tumor size for preoperative risk stratification of gastrointestinal stromal tumors (GISTs) in a Chinese population, as published in the European Journal of Surgical Oncology. The study showed an underestimation of the sizes of gastric GISTs by 0.30 cm when compared with…

Next post in GIST News Briefs